Trimarchi Thomas
President and CFO
Trimarchi Thomas has filed 6 SEC Form 4 filings (12 transaction rows) across 1 company, with disclosures dating back to 2025. 6 of those filings fall inside the rolling window. Most recent filing: Aug 18, 2026.
On the most recent filing, Trimarchi Thomas is listed as President and CFO at BridgeBio Pharma, Inc. Inside the rolling window, Trimarchi Thomas reported no open-market purchases and 3 open-market sales totaling $3.0M in BBIO. The largest disclosed transaction in the window is a sale of 16,934 BBIO shares on Nov 17, 2025, worth $1.1M.
Companies traded
Other insiders at BBIO
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$3.0M
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Trimarchi Thomas made?
Trimarchi Thomas has filed 6 SEC Form 4 filings (12 transaction rows) across 1 company since 2025.
Which companies does Trimarchi Thomas trade?
Trimarchi Thomas has filed SEC Form 4 disclosures for 1 company, including BBIO.
When was Trimarchi Thomas's most recent SEC Form 4 filing?
Trimarchi Thomas's most recent SEC Form 4 filing on Tracefour is dated Aug 18, 2026.
What is Trimarchi Thomas's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Trimarchi Thomas is listed as President and CFO.
What is Trimarchi Thomas's total buy and sell value in the current window?
Inside the rolling retention window, Trimarchi Thomas bought $0 and sold $3.0M based on SEC Form 4 filings.
What was Trimarchi Thomas's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 16,934 BBIO shares on 2025-11-17, worth $1.1M, per SEC Form 4 filings.